Company Profile

KeraCure LLC
Profile last edited on: 3/19/2007      CAGE: 47EF7      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1999
First Award
2002
Latest Award
2002
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

101 North Wacker Drive Suite 610
Chicago, IL 60606
   (312) 780-7442
   info@keracure.com
   www.keracure.com
Location: Single
Congr. District: 07
County: Cook

Public Profile

KeraCureĀ™ was formed to commercialize a simplified cell-based dressing that has utility across a number of medical disciplines. The firm's leading device, the KeraPacĀ™ dressing, is an interactive wound covering comprised of living human cells to be used in the treatment of chronic wounds. KeraCure believes its proprietary KeraPac has a number of advantages for patients and health care providers and will replace existing competitive products on the market today. KeraCure's unique, cell-based technology addresses one of the most pressing current and future medical challenges-effective treatment of chronic wounds. As the aging population continues to expand, the incidence of chronic wounds is increasing significantly. KeraCure believes that its KeraPac will improve the lives of more than 10 million patients requiring treatment each year. The chronic wound treatment market consists of multiple applications resulting in billions of dollars expended annually worldwide. KeraCure has a strong intellectual property position with assignments in five patents in the U.S., with PCT applications in Europe and has filed other key applications broadening the use of the platform. KeraCure has developed a plan to protect and enhance its core technology which will strengthen the long-term commercial value of these patents. KeraCure is currently conducting a Multicenter Pivotal Trial in the treatment of diabetic foot ulcers and will seek regulatory approval * Diabetic Foot Ulcers o Due to poor circulation and/or lack of sensation, diabetics often develop foot ulcers from traumatic or pressure related events such as cuts or shoes that do not fit correctly. These ulcers are the leading cause of hospitalization among diabetics in the U.S. * Venous Stasis Ulcers o Venous ulcers are caused by the cessation or impairment of venous flow in the lower extremity. Ulceration occurs as an end result of sustained high pressure in the veins. * Pressure Ulcers o Pressure ulcers are caused by prolonged pressure on an area of the body having a bony prominence with a thin covering of flesh, such as the "tailbone", hips, heels, elbows and shoulder blades.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $194,903
Project Title: Novel keratinocyte-based therapy for chronic wounds
2002 1 NIH $117,396
Project Title: Cell Viability on a Novel Cell-Therapy Platform

Key People / Management

  Gretchen S Johnson -- President/Chief Operating Officer

  Belinda S Adamson

  Melissa Meek -- Clinical Trials Manager

  Wendi E Olson Ramsay -- Chief Financial Officer

  Riley S Rees

  Susan F Schaeffer -- Vice President of Research and Development

Company News

There are no news available.